SBP Group Unveils 21 Studies for Upcoming Oncology Conference, Including 5 Oral Presentations
Stock News
Yesterday
SBP GROUP (01177) announced that its subsidiary will present 21 new research findings at the 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting, including five oral presentations.
The studies will cover investigational drug TQB3454 (an IDH1 inhibitor) and several marketed products, including Anlotinib Capsules (brand name: Fukevi®), TQB2450 Injection (brand name: Andewei®), Ebgstem Alfa Injection (brand name: Yilishu®), and Penpulimab Injection (brand name: Annike®).
The research spans multiple therapeutic areas such as pancreatic cancer, lung cancer, renal cell carcinoma, gastrointestinal tumors, soft tissue sarcoma, thyroid cancer, and breast cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.